Immunology of human gastric cancer: A preliminary report

The immunological spectrum in fifteen patients with gastric cancer is presented. Patients were divided in three groups. Those with nonadvanced cancer, those with advanced but resectable lesions and those with advanced but nonresectable tumors. Preoperatively, elevated levels of circulating immune co...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1982-05, Vol.49 (9), p.1810-1816
Main Authors: Blanca, Isaac, Grases, Pedro J., Matos V, Marcos, Contreras, Carmen Elena, Ochoa, Mariangel, Wright, Harlam, Bianco C, Nicolàs
Format: Article
Language:English
Subjects:
Adult
Aged
Antibody-Dependent Cell Cytotoxicity
Antigen-Antibody Complex - analysis
Cell Migration Inhibition
Female
Humans
Leukocyte Migration-Inhibitory Factors - analysis
Lymphocyte Activation
Lymphocyte Culture Test, Mixed
Male
Middle Aged
Prospective Studies
Stomach Neoplasms - immunology
Stomach Neoplasms - surgery
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The immunological spectrum in fifteen patients with gastric cancer is presented. Patients were divided in three groups. Those with nonadvanced cancer, those with advanced but resectable lesions and those with advanced but nonresectable tumors. Preoperatively, elevated levels of circulating immune complexes (CIC) associated with hyporesponsiveness to phytohemagglutinin (PHA) and in mixed lymphocyte culture (MLC) as well as a positive leukocyte inhibitory serum factor (LIF‐S) were found in nearly half of the patients. Inhibitory or enhancing autologous serum factors were detected. Postoperatively, immunologic parameters return to normal in patients with nonadvanced cancer, while in advanced cancer, antibody and cell‐mediated immune response remained altered, with some changes associated with chemotherapy. These findings are probably related with the presence or absence of tumor and offer a distinct approach in evaluating the immunologic response of a tumor‐bearing patient.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19820501)49:9<1810::AID-CNCR2820490913>3.0.CO;2-2